查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1580001

脈絡膜新生血管市場：按產品類型、治療類型、疾病類型、最終用戶分類 - 全球預測 2025-2030

Choroidal Neovascularization Market by Product Type (Biologics, Devices, Drugs), Treatment Type (Anti-VEGF Drugs, Laser Photocoagulation, Photodynamic Therapy), Disease Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

脈絡膜新生血管市場2023年估值為59.5億美元，預計到2024年將達到63.8億美元，複合年成長率為7.57%，到2030年達到99.3億美元。

脈絡膜新生血管（CNV）是眼球脈絡膜層新血管的形成，通常會導致嚴重的視力障礙和老齡化黃斑部病變（AMD）等疾病。隨著世界老化導致 AMD 盛行率增加，對創新治療方法的需求推動了 CNV 治療市場的發展。目前的治療方法包括抗 VEGF（血管內皮生長因子）療法、雷射療法和動態療法，最終用戶包括眼科診所、醫院和眼科專科醫療中心。市場成長受到藥物輸送系統的進步、患者意識的提高以及專注於提高治療效果的持續研究的影響。此外，技術創新，特別是生技藥品和基因治療領域的技術創新，為公司擴大產品系列提供了重要機會。然而，治療成本上升、監管障礙和潛在副作用等挑戰需要持續的研究和創新，以確保更有效和負擔得起的解決方案。

主要市場統計
基準年[2023] 59.5億美元
預測年份 [2024] 63.8億美元
預測年份 [2030] 99.3億美元
複合年成長率（%） 7.57%

關鍵的商機在於開發緩釋性和個人化醫療，利用遺傳標記制定個人化治療計畫。公司可以投資合作研究，探索新的作用機制和聯合治療，進而改善患者的治療效果。儘管存在這些治療機會，但市場仍面臨抗治療性和 CNV 病理生理學複雜性等限制，這使得通用治療方法的開發變得複雜。此外，經濟因素和獲得醫療保健的問題對市場滲透提出了挑戰，特別是在低收入地區。具有高潛力的創新領域包括用於最佳化治療通訊協定的人工智慧輔助診斷，以及旨在精確靶向 CNV 組織並減少對周圍眼部結構的附帶損害的人工智慧輔助診斷以及奈米技術增強的藥物傳輸系統。為了發展您的業務，專注於與研究機構合作並積極參與全球臨床試驗，以獲得對新趨勢和技術的寶貴見解，並與動態發展的市場保持聯繫，這有助於企業在競爭中保持競爭力。

市場動態：快速發展的脈絡膜新生血管市場的關鍵市場洞察

供需的動態交互作用正在改變脈絡膜新生血管市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 在高齡化社會中，老齡化黃斑部病變（AMD）和相關疾病的盛行率不斷增加
    • 提高早期診斷和治療意識
  • 市場限制因素
    • 由於治療費用上漲導致可近性下降
  • 市場機會
    • 利用人工智慧利用視網膜影像進行早期診斷
    • 開發緩釋性植入和注射以減少治療次數
  • 市場挑戰
    • 與目前治療相關的可能的副作用和併發症

波特五力：開拓脈絡膜新生血管市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解脈絡膜新生血管市場的外部影響

外部宏觀環境因素在塑造脈絡膜新生血管市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解脈絡膜新生血管市場的競爭狀況

對脈絡膜新生血管市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣脈絡膜新生血管市場供應商的績效評估

FPNV定位矩陣是評估脈絡膜新生血管市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製脈絡膜新生血管市場的成功之路

對脈絡膜新生血管市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 在高齡化社會中，老齡化黃斑部病變（AMD）和相關疾病的盛行率不斷增加
      • 提高早期診斷和治療意識
    • 抑制因素
      • 治療費用高且取得機會有限
    • 機會
      • 利用人工智慧利用視網膜影像進行早期診斷
      • 開發緩釋植入和注射以減少治療頻率
    • 任務
      • 與目前治療方法相關的潛在副作用和併發症
  • 市場區隔分析
    • 產品類型：針對性的作用機制和功效正在增加對生物製藥的偏好。
    • 最終用戶：可用的治療選擇範圍廣泛，包括雷射療法、抗 VEGF 注射和動態療法，正在增加醫院的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章脈絡膜新生血管市場：依產品類型

  • 生物製藥
  • 裝置
  • 藥物

第7章依治療類型分類的脈絡膜新生血管市場

  • 抗VEGF藥物
  • 雷射光凝
  • 動態療法

第8章脈絡膜新生血管市場：依疾病類型

  • 類型1
  • 2型
  • 類型3

第9章脈絡膜新生血管市場：依最終用戶分類

  • 醫院
  • 眼科診所
  • 調查機構

第10章美洲脈絡膜新生血管市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區脈絡膜新生血管市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲脈絡膜新生血管市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Biocon Biologics 旨在透過 FDA核准Yesafili 來擴大市場，Yesafili 是一種與阿柏西普相容的眼科生物學名藥。
    • 參天製藥和拜耳製藥在日本推出了 Eylea 8mg，這是一種高濃縮製劑，可改善 nAMD 和 DME 的治療。
    • 山德士以 1.7 億美元從 Coherus Biosciences 收購生物相似藥雷珠單抗 CIMERLI，加強其在眼科市場的影響力和產品組合
  • 戰略分析和建議

公司名單

  • Adverum Biotechnologies
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch+Lomb Corporation
  • Bausch Health
  • Bayer AG
  • Biogen, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Clearside Biomedical
  • F. Hoffmann-La Roche Ltd.
  • Genentech USA, Inc.
  • Genentech, Inc.
  • Iveric Bio
  • Kodiak Sciences
  • Kodiax Pharmaceuticals
  • Novartis AG
  • PulseSight Therapeutics
  • Regeneron Pharmaceuticals Inc.
  • Samsung Bioepis.
  • Sandoz Inc.
  • Santen Pharmaceutical Co. Ltd.
Product Code: MRR-976C0ED91BDE

The Choroidal Neovascularization Market was valued at USD 5.95 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 9.93 billion by 2030.

Choroidal Neovascularization (CNV) involves the formation of new blood vessels in the choroid layer of the eye, often linked to severe vision impairment and conditions like age-related macular degeneration (AMD). The market for CNV treatment is driven by the necessity for innovative therapeutic approaches due to the rising prevalence of AMD among aging populations globally. Current applications include anti-VEGF (vascular endothelial growth factor) therapies, laser treatment, and photodynamic therapy, with end-users spanning ophthalmology clinics, hospitals, and specialized eye care centers. Market growth is influenced by advancements in drug delivery systems, increasing patient awareness, and ongoing research focused on improving treatment efficacy. Moreover, technological innovations, particularly in biologics and gene therapy, present significant opportunities for companies to expand their product portfolios. However, challenges such as the high cost of treatments, regulatory hurdles, and potential side effects necessitate continuous research and innovation to ensure more effective and affordable solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 5.95 billion
Estimated Year [2024] USD 6.38 billion
Forecast Year [2030] USD 9.93 billion
CAGR (%) 7.57%

Key opportunities lie in the development of sustained-release drug formulations and personalized medicine, leveraging genetic markers for individualized treatment plans. Companies could invest in collaborative research efforts to explore novel mechanisms of action and combination therapies that could enhance patient outcomes. Despite these opportunities, the market faces limitations such as treatment resistance and the complexity of CNV pathophysiology, which complicates the development of universal treatments. Additionally, economic factors and healthcare accessibility issues pose challenges to market penetration, particularly in low-income regions. Areas of innovation with high potential include AI-assisted diagnostics to optimize treatment protocols, and nanotechnology-enhanced drug delivery systems designed to target CNV tissues precisely and reduce collateral damage to surrounding eye structures. For business growth, focusing on partnerships with research institutions and actively participating in global clinical trials can provide valuable insights into emerging trends and technologies, helping firms remain competitive in a dynamic and evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Choroidal Neovascularization Market

The Choroidal Neovascularization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
    • Enhanced awareness about early diagnosis and treatment
  • Market Restraints
    • High cost of treatment limiting the accessibility
  • Market Opportunities
    • Leveraging artificial intelligence for early diagnosis using retinal imaging
    • Developing sustained-release implants and injections for reducing the frequency of treatments
  • Market Challenges
    • Potential side effects and complications associated with current treatments

Porter's Five Forces: A Strategic Tool for Navigating the Choroidal Neovascularization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Choroidal Neovascularization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Choroidal Neovascularization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Choroidal Neovascularization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Choroidal Neovascularization Market

A detailed market share analysis in the Choroidal Neovascularization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Choroidal Neovascularization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Choroidal Neovascularization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Choroidal Neovascularization Market

A strategic analysis of the Choroidal Neovascularization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Choroidal Neovascularization Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Bausch + Lomb Corporation, Bausch Health, Bayer AG, Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Clearside Biomedical, F. Hoffmann-La Roche Ltd., Genentech USA, Inc., Genentech, Inc., Iveric Bio, Kodiak Sciences, Kodiax Pharmaceuticals, Novartis AG, PulseSight Therapeutics, Regeneron Pharmaceuticals Inc., Samsung Bioepis., Sandoz Inc., and Santen Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Choroidal Neovascularization Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Biologics, Devices, and Drugs.
  • Based on Treatment Type, market is studied across Anti-VEGF Drugs, Laser Photocoagulation, and Photodynamic Therapy.
  • Based on Disease Type, market is studied across Type 1, Type 2, and Type 3.
  • Based on End-User, market is studied across Hospitals, Ophthalmology Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
      • 5.1.1.2. Enhanced awareness about early diagnosis and treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment limiting the accessibility
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging artificial intelligence for early diagnosis using retinal imaging
      • 5.1.3.2. Developing sustained-release implants and injections for reducing the frequency of treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Potential side effects and complications associated with current treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product type: Increasing preference for biologics due to their targeted mechanism of action and efficacy.
    • 5.2.2. End-user: Increasing need in hospitals due to presence of a wide range of treatment options, including laser therapy, anti-VEGF injections, and photodynamic therapy.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Choroidal Neovascularization Market, by Product Type

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Devices
  • 6.4. Drugs

7. Choroidal Neovascularization Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Anti-VEGF Drugs
  • 7.3. Laser Photocoagulation
  • 7.4. Photodynamic Therapy

8. Choroidal Neovascularization Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Type 1
  • 8.3. Type 2
  • 8.4. Type 3

9. Choroidal Neovascularization Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Ophthalmology Clinics
  • 9.4. Research Institutes

10. Americas Choroidal Neovascularization Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Choroidal Neovascularization Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Choroidal Neovascularization Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Biocon Biologics receives FDA approval for Yesafili, an ophthalmology biosimilar interchangeable with aflibercept, targeting market growth
    • 13.3.2. Santen Pharmaceutical and Bayer Yakuhin launched Eylea 8mg in Japan to improve nAMD and DME treatment with higher concentration formula
    • 13.3.3. Sandoz USD 170 million acquisition of biosimilar ranibizumab CIMERLI from Coherus BioSciences bolsters ophthalmology market presence and portfolio
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adverum Biotechnologies
  • 2. Apellis Pharmaceuticals, Inc.
  • 3. Astellas Pharma Inc.
  • 4. Bausch + Lomb Corporation
  • 5. Bausch Health
  • 6. Bayer AG
  • 7. Biogen, Inc.
  • 8. Chugai Pharmaceutical Co., Ltd.
  • 9. Clearside Biomedical
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech USA, Inc.
  • 12. Genentech, Inc.
  • 13. Iveric Bio
  • 14. Kodiak Sciences
  • 15. Kodiax Pharmaceuticals
  • 16. Novartis AG
  • 17. PulseSight Therapeutics
  • 18. Regeneron Pharmaceuticals Inc.
  • 19. Samsung Bioepis.
  • 20. Sandoz Inc.
  • 21. Santen Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. CHOROIDAL NEOVASCULARIZATION MARKET RESEARCH PROCESS
  • FIGURE 2. CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHOROIDAL NEOVASCULARIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHOROIDAL NEOVASCULARIZATION MARKET DYNAMICS
  • TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LASER PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2023